medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2020, Number 1

<< Back Next >>

Acta Med 2020; 18 (1)

Microbubble-contrast ultrasound for the non-invasive diagnosis of hepatocarcinoma

Ramírez GVA, Vega LCA, Pérez GAF, Paredes MC, Quiroz CÓ

Language: Spanish
References: 10
Page: 67-70
PDF size: 192.92 Kb.


ABSTRACT

Contrast-Enhanced Ultrasound (CEUS) was approved in 2016 for its use in hepatic lesions. Ever since its approval, it has been used for the diagnosis of Hepatocellular Carcinoma (HCC) with a similar sensitivity and specificity than Computed Tomography and Magnetic Resonance. The microbubles are administered intravenously and have pulmonary elimination, which makes them an ideal study for patients with chronic kidney disease. CEUS allows us to evaluate hepatic lesions in real time with their different contrast phases, and recognize the specific features of HCC that according to the LI-RADS classification (Liver Imaging Reporting and Data System), it can be diagnosed with high accuracy. CEUS has many advantages and disadvantages for the diagnosis and follow up of HCC, they should all be taken into consideration during the evaluation of these patients and consider CEUS as a valuable diagnostic tool.


REFERENCES

  1. Ferraioli G, Meloni M. Contrast-enhanced ultrasonography of the liver using SonoVue. Ultrasonography. 2018; 37: 25-35.

  2. Konopke R, Kersting S, Bergert H. Contrast-enhanced ultrasonography to detect liver metastases : a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy. Int J Colorectal Dis. 2007; 22: 201.

  3. Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F et al. How to perform contrasted-enhanced ultrasound (CEUS). Ultasound Int Open. 2017; E2-E15.

  4. Piscaglia F, Bolondi L, Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultra-sound Contrast Agents. The safety of Sonovue in abdominal applications: retrospective analysis of 23,188 investigations. Ultrasound Med Bio. 2006; 32 (9): 1369-1375.

  5. Wei K, Mulvagh SL, Carson L, Davidoff R, Gabriel R, Grimm RA et al. The safety of DeFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr. 2008; 21 (11): 1202-1206.

  6. Claudon M, Dietrich CF, Choi BI. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver -update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013; 39: 187.

  7. Liu X, Jang HJ, Khalili K, Kim TK, Atri M. Successful integration of contrast enhanced us into routine abdominal imaging. Radiographics. 2018; 38: 1454-1477.

  8. American College of Radiology. ACR CEUS LI-RADS 2017 [Internet]. American College of Radiology. Disponible en: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CEUS-LI-RADS-v2017 [accesado el 31 de agosto de 2018].

  9. Seitz K, Bernatik T, Strobel D, Blank W, Friedrich-Rust M, Strunk H, Greis C et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs MRI--a prospective comparison in 269 patients. Ultraschall Med. 2010; 31: 492.

  10. lsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Marks RM et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019; 6, 46-69.




2020     |     www.medigraphic.com